Immutep Reports New Data In Head And Neck Cancer At ESMO Immuno-Oncology 2024; Complete Response Rate Increases To 12.9% And 16.1%, According To RECIST 1.1 And IRECIST, Respectively; Treatment Continues To Be Well Tolerated
Immutep Reports New Data In Head And Neck Cancer At ESMO Immuno-Oncology 2024; Complete Response Rate Increases To 12.9% And 16.1%, According To RECIST 1.1 And IRECIST, Respectively; Treatment Continues To Be Well Tolerated
- Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1
- Positively, median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%, both well above historical controls
- Complete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectively
- Treatment continues to be well tolerated
- 數據顯示，針對難治性頭頸癌患者，PD-L1 CPS
- 積極的消息是，媒體總體生存期尚未達到，12個月的總體生存率爲67%，均高於歷史對照。
- 根據RECISt 1.1和iRECISt，完全反應率分別增加至12.9%和16.1%。
- 治療繼續得到良好的耐受性。
SYDNEY, AUSTRALIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive clinical results from Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb trial. This study evaluates eftilagimod alpha (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) in first line recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients with negative PD-L1 expression.
澳洲悉尼，2024年12月12日（全球通訊社）——Immutep有限公司（（ASX: IMm，納斯達克:IMMP）("Immutep"或"公司"），一家臨床階段生物技術公司，正在開發針對癌症和自身免疫性疾病的新型LAG-3免疫療法，今天宣佈TACTI-003（KEYNOTE-C34）第二階段b期臨床試驗的積極臨床結果。本研究評估了eftilagimod alpha（efti）與MSD（默沙東，位於新澤西州Rahway，美國）的抗PD-1療法KEYTRUDA（pembrolizumab）聯合用於第一次復發/轉移性頭頸部鱗狀細胞癌（1L HNSCC）患者，且這些患者的PD-L1表達爲陰性。
譯文內容由第三人軟體翻譯。
